Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients
Richard P. Wenzel(Virginia Commonwealth University Medical Center), A Marciniak, Coleman Rotstein(Hamilton Health Sciences), Thomas R. Rogers(Scripps Research Institute), Peter F. Troke, A. Del Favero, C C Kibbler(Royal Free London NHS Foundation Trust), Josephine Mauskopf(RTI Health Solutions), Haran T. Schlamm(Pfizer (United States)), Stephen Morris(University College London)
Cited by 66
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Anidulafungin versus Fluconazole for Invasive Candidiasis
|New England Journal of Medicine|2007|896
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
|Clinical Infectious Diseases|2003|680
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644